Recent Advances in Digestive Tract Tumors: Updates From the 5th Edition of the World Health Organization "Blue Book".


Journal

Archives of pathology & laboratory medicine
ISSN: 1543-2165
Titre abrégé: Arch Pathol Lab Med
Pays: United States
ID NLM: 7607091

Informations de publication

Date de publication:
01 05 2021
Historique:
accepted: 12 05 2020
pubmed: 5 9 2020
medline: 1 6 2021
entrez: 4 9 2020
Statut: ppublish

Résumé

The World Health Organization Classification of Tumours: Digestive System Tumors, 5th edition, was published in 2019 and shows several impactful changes as compared with the 4th edition published in 2010. Changes include a revised nomenclature of serrated lesions and revamping the classification of neuroendocrine neoplasms. Appendiceal goblet cell adenocarcinoma is heavily revised, and intrahepatic cholangiocarcinoma is split into 2 subtypes. New subtypes of colorectal carcinoma and hepatocellular carcinoma are described. Precursor lesions are emphasized with their own entries, and both dysplastic and invasive lesions are generally recommended to be graded using a 2-tier system. Hematolymphoid tumors, mesenchymal tumors, and genetic tumor syndromes each have their own sections in the 5th edition. New hematolymphoid lesions include monomorphic epitheliotropic intestinal T-cell lymphoma; duodenal-type follicular lymphoma; intestinal T-cell lymphoma, not otherwise specified; and indolent T-cell lymphoproliferative disorder of the gastrointestinal tract. This paper will provide an in-depth look at the changes in the 5th edition as compared with the 4th edition. To provide a comprehensive, in-depth update on the World Health Organization classification of digestive tumors, including changes to nomenclature, updated diagnostic criteria, and newly described entities. The 5th edition of the World Health Organization Classification of Tumours: Digestive System Tumours, as well as the 4th edition. The World Health Organization has made many key changes in its newest update on tumors of the digestive system. Pathologists should be aware of these changes and incorporate them into their practice as able or necessary.

Identifiants

pubmed: 32886739
pii: 442305
doi: 10.5858/arpa.2020-0047-RA
doi:

Substances chimiques

Biomarkers, Tumor 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

607-626

Informations de copyright

© 2021 College of American Pathologists.

Auteurs

Raul S Gonzalez (RS)

The Department of Pathology, Beth Israel Deaconess Medical Center, Boston, Massachusetts (Gonzalez).

Anwar Raza (A)

The Department of Pathology and Human Anatomy, Loma Linda University, Loma Linda, California (Raza, Propst).

Robert Propst (R)

The Department of Pathology and Human Anatomy, Loma Linda University, Loma Linda, California (Raza, Propst).

Oyedele Adeyi (O)

The Department of Pathology, University of Minnesota, Minneapolis (Adeyi, Bateman).

Justin Bateman (J)

The Department of Pathology, University of Minnesota, Minneapolis (Adeyi, Bateman).

Sabrina C Sopha (SC)

The Department of Pathology, University of Maryland Baltimore Washington Medical Center, Glen Burnie (Sopha).

Janet Shaw (J)

The Joint Pathology Center, Silver Spring, Maryland (Shaw, Auerbach).

Aaron Auerbach (A)

The Joint Pathology Center, Silver Spring, Maryland (Shaw, Auerbach).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH